Skip to content

sugammadex and neostigmine for reversal of rocuronium induced muscle relaxation in patients undergoing general anaesthesia

Comparison of sugammadex and neostigmine for reversal of rocuronium induced muscle relaxation in patients undergoing general Anaesthesia: A Randomized Controlled Trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057991
Enrollment
98
Registered
2023-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: INJ. SUGAMMADEX: GROUP 1: Inj. Sugammadex 2mg/kg will be given at the time of reversal after a peripheral nerve stimulator evaluation in which it shows a reading of 0.4 on train of four

Sponsors

ROHILKHAND MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age: 18 years to 60 years 2. Informed and written consent from patients 3. ASA grade I & II 4. Elective surgeries under general anaesthesia

Exclusion criteria

Exclusion criteria: 1. Patient with suspected difficult intubation 2. Patients with neuromuscular disorders 3. Patients with known or suspected significant renal or hepatic dysfunction. 4. Allergy or contraindication to any drug affecting neuromuscular block or general anaesthesia 5. Pregnancy 6. Breastfeeding

Design outcomes

Primary

MeasureTime frame
1.To compare fast and complete recovery of neuromuscular function between sugammadex and neostigmine. 2.To determine post operative residual curarization incidences in both groups. 3.To assess hemodynamic changes in both groups. 4.To document side effects after reversal in both groups Timepoint: In 30, 60, and 120 minutes, the level of post operative residual curarization and postoperative discomfort will be evaluated. The patients will be transferred to the ward after being monitored for 2 hours for adverse symptoms such as nausea, vomiting, bradycardia, hypotension, sedation, and others.

Secondary

MeasureTime frame
NONETimepoint: NONE

Countries

India

Contacts

Public ContactDR ANKUR GARG

Rohilkhand medical collega dn hospital bareilly

rinkichandra@yahoo.com8279783945

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026